Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $5.3 million, up 128% from $2.3 million in Q4 2024 [21] - Full year 2025 revenue was $13.6 million, a 5% increase from $12.9 million in 2024 [22] - Gross profit for Q4 2025 was $2.7 million, up 226% compared to Q4 2024 [22] - Gross margin for Q4 2025 was 50.9%, representing a 1,530 basis points increase from Q4 2024 [23] - Net loss for Q4 2025 was $5.9 million, compared to a net loss of $10.4 million in Q4 2024 [25] - Full year net loss was $35.6 million, down from $40.7 million in 2024 [26] Business Line Data and Key Metrics Changes - Sold 16 units in Q4 2025 compared to 9 units in Q4 2024, indicating increased demand across all business lines [21] - Significant revenue growth in the second half of 2025, generating $8.7 million compared to $4.8 million in the first half [22] - R&D expenses decreased by 25% in Q4 2025 compared to Q4 2024, reflecting a transition to a commercial growth stage [24] Market Data and Key Metrics Changes - FDA clearance for the updated Swoop system in December 2025, enhancing its clinical utility in stroke workflows [6] - Approval of the first-generation Swoop system in India opens a new market opportunity [7] - Positive market feedback on the Swoop system with Optive AI software, indicating readiness for broad adoption [17] Company Strategy and Development Direction - Focus on continuous innovation and market development, with plans for one to two software releases per year [9] - Expansion into neurology offices and international markets as key growth vectors [14][17] - Emphasis on generating clinical and economic evidence to support sales and adoption [6][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of the Swoop system and its unique position in the ultra-low field MRI market [5] - Anticipated revenue growth for 2026 between $20-$22 million, representing a 55% increase at the midpoint [28] - Expected gross margin for 2026 to be in the range of 50%-55% [29] Other Important Information - The company raised over $20 million in equity and $15 million in long-term debt to strengthen its capital position [19][20] - Cash burn for Q4 2025 was $5.7 million, down 30% from Q4 2024 [26] - Cash runway extended into 2028 due to recent financing [30] Q&A Session Summary Question: Key assumptions surrounding 2026 guidance - Management indicated that guidance is tied to growth catalysts across three business verticals, with multi-unit systems and IDNs playing a significant role [35][37] Question: Pipeline status and strength - Management confirmed that the pipeline remains strong and diversified, with multiple IDN deals in progress [41][42] Question: Service revenue trends - Management acknowledged that service revenue was lower in Q4 due to accounting adjustments but expects long-term growth in this area [55]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $5.3 million, up 128% from $2.3 million in Q4 2024 [19] - Full year 2025 revenue was $13.6 million, a 5% increase from $12.9 million in 2024 [21] - Gross profit for Q4 2025 was $2.7 million, up 226% compared to Q4 2024 [21] - Gross margin for Q4 2025 was 50.9%, representing a 1,530 basis points increase from Q4 2024 [22] - Net loss for Q4 2025 was $5.9 million, compared to a net loss of $10.4 million in Q4 2024 [24] - Full year net loss was $35.6 million, down from $40.7 million in 2024 [25] Business Line Data and Key Metrics Changes - The company sold 16 units in Q4 2025 compared to 9 units in Q4 2024, indicating increased demand across all business lines [20] - The introduction of the next-generation Swoop system and Optive AI software has led to significant growth in the second half of 2025 [21][28] Market Data and Key Metrics Changes - The FDA clearance of the updated Swoop software in December 2025 has enhanced the system's capabilities, particularly in stroke workflows [6] - The approval of the first-generation Swoop system in India opens a new market opportunity for the company [7] Company Strategy and Development Direction - The company aims to expand its market presence in neurology offices and international markets, leveraging the strong clinical and economic value of its technology [4][16] - Continuous innovation and the introduction of new software releases are central to the company's strategy for growth [9][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of the Swoop system, citing strong market feedback and the potential for broader adoption [5][16] - The company anticipates revenue growth between $20 million and $22 million for 2026, representing a year-over-year growth of approximately 55% [27] Other Important Information - The company has strengthened its capital position by raising over $20 million in equity and $15 million in debt, extending its cash runway into 2028 [18][26] - The company is focused on reducing cash burn, which was down 30% in Q4 2025 compared to the previous year [25][26] Q&A Session Summary Question: Key assumptions surrounding 2026 guidance - Management indicated that the guidance is based on growth catalysts across three business verticals, with expectations for progressive strengthening of revenue throughout 2026 [33][35] Question: Pipeline status and multi-unit orders - Management confirmed that the pipeline remains strong and diversified, with several IDN deals in progress, although larger deals may take longer to finalize due to budget cycles [40][41] Question: Service revenue trends - Management acknowledged that service revenue was lower in Q4 due to accounting adjustments related to core technology upgrades, but expects growth in the long term [53][54]